Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and remains one of the leading causes of cancer-related deaths worldwide.

Despite advances in targeted therapies and immunotherapy, substantial molecular heterogeneity continues to limit accurate prognostic prediction and effective treatment selection.

While metabolic reprogramming is increasingly recognised as a hallmark of HCC, the contribution of lipid droplet-associated genes (LDAGs) to tumour classification and disease progression has remained poorly defined.

In a recent study published in Genes & Diseases, researchers from Chongqing Medical University developed a comprehensive molecular classification framework based on LDAGs to better understand the metabolic diversity of HCC.

By integrating transcriptomic and clinical data from 1,834 patients across multiple independent cohorts, the investigators identified biologically distinct HCC subtypes with unique molecular features, clinical outcomes, and therapeutic vulnerabilities.

Using unsupervised consensus clustering of 122 LDAGs, the researchers classified HCC into three molecular subtypes (C1–C3).

The C1 subtype represented the most aggressive form of disease, exhibiting advanced tumour stage, increased vascular invasion, enhanced inflammatory infiltration, and significantly poorer overall survival than the other subtypes.

Genomic analyses further demonstrated subtype-specific mutation profiles, with TP53 mutations enriched in C1 and CTNNB1 mutations predominating in C3, reinforcing the relationship between lipid metabolism and established oncogenic pathways.

Functional enrichment and pathway analyses revealed distinct metabolic and signalling programmes across the three subtypes, highlighting the biological significance of LDAG expression patterns.

Drug sensitivity analyses further suggested that tumours belonging to the aggressive C1 subtype may exhibit increased responsiveness to sorafenib, indicating that LDAG-based stratification could help guide precision treatment strategies for patients with advanced HCC.

To identify molecular drivers underlying tumour aggressiveness, the researchers pinpointed five hub genes—PLIN3, SET, CKAP4, RAP1B, and PISD—with PLIN3 emerging as the strongest prognostic biomarker.

Experimental validation demonstrated that silencing PLIN3 reduced intracellular lipid accumulation, inhibited HCC cell proliferation and migration, and suppressed tumour growth.

Conversely, PLIN3 overexpression promoted aggressive tumour behaviour, establishing its critical role in metabolic reprogramming and HCC progression.

Overall, this study establishes LDAG signatures as a robust framework for classifying HCC into clinically meaningful metabolic subtypes.

By identifying PLIN3 as both a prognostic biomarker and a potential therapeutic target, the findings provide valuable insights into the metabolic mechanisms driving HCC heterogeneity and offer a foundation for developing more personalised prognostic and therapeutic strategies for liver cancer.

Source: Compuscript Ltd